Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Graviton","pharmaFlowCategory":"D","amount":"$517.5 million","upfrontCash":"Undisclosed","newsHeadline":"Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Beijing Tide Pharmaceutical

    Menu

    Beijing Tide Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Beijing Tide Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide

              Details:

              The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.

              Lead Product(s): TDI01

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TDI01

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Graviton

              Deal Size: $517.5 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY